HIV Prevention

HIV Cells in Semen Infect Through RNA Transmission

In early 2010, scientists at the University of California San Diego’s Center for AIDS Research (CFAR) discovered that seminal HIV infection among men who have sex with men is transmitted through the HIV cell’s RNA, and not the DNA as was previously thought. Later that year it was determined that this is also the case for women who are infected through sex with men – that is, through HIV cells in semen transmitting their RNA structure to the newly infected individual. Understanding this connection is critical, because, “If we want to stop the HIV epidemic, then we must know the mechanisms by which HIV uses human sex to spread,” according to the principal researcher, Davey Smith, MD, MAS. Smith is an associate professor of medicine at the University of California’s San Diego’s Division of Infectious Diseases, and is director of the CFAR’s Viral Pathogenesis Core.

The scientists made this initial discovery of the virus’s transmission by studying male partners in which one man had recently infected the other man. They compared the genetic characteristics of the HIV cells in both partners, knowing that the virus mutates at an extraordinary rate. They learned that there was more of a shared commonality between the viruses found in the seminal plasma – the semen and fluids surrounding them – than the viruses that were located in the seminal cells. HIV’s DNA is commonly found in the host’s cells, where RNA is mostly stored in the host’s plasma. With this asymmetrical commonality between the virus found in the plasma versus the virus inside the host’s cells, the scientists were able to locate the culprit of the initial transmission, which is the virus’s RNA; with this asymmetrical commonality found in every partnership of the men they studied, they determined that it is not a mix of HIV RNA and DNA infecting an individual, but that the RNA, alone, was the transmitter.

Now knowing this source of HIV transmission, scientists and researchers have been able to develop several weapons against HIV infection over the past five years. The HIV cells in semen are now understood more, and with this understanding researchers have been able to determine and develop several things. One discovery is that if a person has no detectable amount of HIV in their bloodstream, as they have been recently infected or because they are taking a successful regimen of antiretroviral medications, there can still be a contagious amount of HIV cells in their semen – and though the possibility of infection is low at that point, it is still possible. Researchers have also been able to develop vaginal gels and ointments – called vaginal microbicides – which are able to attack the HIV cell’s RNA before transmission can take place by infected semen, along with further developing antiretroviral medications which target the virus’s RNA and make it impotent towards further transmission. Though this discovery has not led to a cure within the past five years, it has certainly brought us closer to that possible cure, and has helped prevent further transmission of HIV for thousands.

Prevent the Spread of HIV Infection

Prevent the Spread of HIV Infection: Nanofiber-Based Technology Could Help

Human Immunodeficiency Virus (HIV) is spread through direct contact with blood, semen, pre-seminal fluid, vaginal fluids, fecal matter, breast milk, and other heavy fluids that our bodies produce. This virus attacks the T lymphocytes, a type of white blood cell that is a part of your immune system and prevents infections and diseases. Without treatment to prevent the virus from replicating itself, these T Cells eventually will become depleted. It is estimated that more than one million people over the age of thirteen are living with HIV infection. Of this number, roughly two hundred thousand infected people are unaware that they are HIV positive. The current therapies that stop the virus from replicating and spreading through the bloodstream will also stop the negative effects of HIV. However, they do not completely rid the body of the virus and do not prevent the possibility of further infection from occurring. Fortunately, there are new treatments in development that could actually prevent the spread of HIV infection around the world.

Of these new forms of prevention being developed, a group of researchers based out of the University of Missouri-Kansas City School of Pharmacy are testing a novel nanofiber-based technology. The aim is to prevent the transmission of HIV through vaginal mucus membranes. This vaginal-based drug is applied to the area prior to sexual contact, and is designed to take effect upon the presence of semen enzymes. The drug inactivates and kills any present HIV cells in the enzymes—prior to exposure and penetration of vaginal fluids. This is the main cause of heterosexual HIV transmission, HIV infected semen enzymes penetrating into the vaginal fluids and infecting the host, and this technology has been shown to effectively prevent the spread of HIV infection in this matter. They are working on using this technology in male-to-male sexual contact as well, and preliminary research looks positive.

Low Cholesterol Helps HIV Immunity

Low Cholesterol Helps HIV Immunity: A Link that can Prevent AIDS Progression

With current HIV therapies, those who are HIV-positive can live for decades without the infection progressing to AIDS. The antiretroviral treatments given today greatly improve the quality of life for many. In the past, once a person became infected with HIV, it would only take 1-2 years for the infection to take hold and overwhelm the immune system. High mortality rates were a direct result of this quick-moving process. After decades of meticulous study, research and record-keeping, certain links have been discovered that could help fight off the infection within the body, namely low cholesterol helps HIV immunity.

While the average person once infected with HIV would manifest with AIDS quickly if left untreated, there is a small percentage of the population that could avoid this. Some could go as long as 10 years or more without HIV progressing to AIDS. Through careful documentation, the link may have been discovered. The common denominator seems to be low levels of cholesterol in certain immune system cells. The interesting part is that this level has nothing to do with blood cholesterol levels. It appears to be an inherent trait and is present even before an infection takes place. Seeing as HIV needs cholesterol within the cells to invade and replicate, low cholesterol helps HIV immunity by greatly slowing down the virus. The result is better protection against HIV and prevention of AIDS. 

While researchers are not exactly sure how this works or why some have this trait, they are hopeful. By investigating further, a new way to treat and prevent AIDS could come about in the near future. The premise that low cholesterol helps HIV immunity has taken over a decade to deduce. Thanks to the painstaking tasks of monitoring and documenting what was observed through the years, these results could mean even better treatment options for those who are HIV-positive and possibly even help in preventing an initial infection.

 

Truvada And Sexually Risky Behavior

Truvada Proves Effective in HIV Prevention

Researchers have wanted to take a closer look into how and why progress has been made in the battle against HIV. Antiretroviral therapy has helped to lower the viral load for thousands of HIV-positive patients, and life expectancy has also increased dramatically in recent years. Most of this is thanks to Truvada, but medical researchers worry that overconfidence in the therapy might promote an increase in unsafe sexual behavior. Researchers questioned whether patients using Truvada might feel so protected that they would exhibit riskier practices.

Truvada can be used as a protection for those at risk for infection, as well as for treating an existing one. Clinical studies conducted over the last few years looked into the effectiveness of the drug, and discovered that risk of infection was reduced by nearly 90%. While researchers were happy with these findings, they wanted to be sure that this effectiveness did not become a false sense of security for those taking it. This type of behavior is known as risk compensation.

Trials were designed to determine how sexual behaviors changed before and after taking Truvada. 2500 people participated in the trial. Half received Truvada, and the other half a placebo. There was no observed increase in risky behavior. Contrary to what they expected, infections continued decreasing. Researchers believe that the counseling and education that accompanied the therapy helped to increase awareness. This type of education continues to be encouraged, as does the use of Truvada. Overall, scientists are pleased with the positive results so far seen by this pioneer drug treatment. It has proven to be effective without increasing risky sexual behavior in those taking it.

New Protein Could Be Breakthrough in HIV Prevention

The race to eradicate HIV and improve the vaccine has led to an exciting new development. Researchers within the last few weeks have published new findings regarding a protein and sugar molecule that has the potential to not only neutralize HIV, but that can connect to various strains of the virus as well.

The protein that was created mimics the outer layer of the HIV. The part of the layer that can bind to antibodies is the area researchers were targeting. This key part of the cell is where neutralizing the virus takes place. One of the factors that make the creation of this protein so important is that it may help scientists answer some of the most complex issues facing the prevention of HIV. For one thing, an antibody that can target multiple strains of the virus is hard to come by. Another problem is the response of the immune system: At times it is beneficial, but other responses can be negative and unwanted. Researchers are hoping that, with this protein, the immune system will be free to respond in a positive, beneficial way. The protein with the sugar molecule is better able to bond to the outer coat of the virus. It is hoped that broad-spectrum antibodies will be allowed to form. If this happens, the antibodies that can do the most neutralizing will have a better chance to complete their task.

Another benefit to the proteins is the potential to trigger a response from the white blood cells that produce antibodies. Should the antibodies produced by these B cells do what researchers are hoping, results could be disastrous for the virus. This aspect is what scientists are focusing on to develop an effective vaccine. Much more information is needed, as well as testing on animal subjects. This does not, however, negate the importance that this finding will have on the future of the battle against HIV.

Go to Top